Inhibition of Tumor Angiogenesis
- 1 September 1994
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 732 (1), 263-272
- https://doi.org/10.1111/j.1749-6632.1994.tb24741.x
Abstract
The exponential growth of solid tumors depends upon induction of new vessel growth, a process mediated by diffusable angiogenic factors produced by tumor cells. By inhibiting angiogenesis, it is now possible to modulate tumor growth and metastasis in laboratory animals. The first described inhibitor of angiogenesis was a protein derived from cartilage. Other important classes of antiangiogenic agents include angiostatic steroids combined with heparin or heparin derivatives, and the synthetic derivatives of fumigallin. As the mechanisms of action of these and other angiostatic agents are being elucidated, it is becoming apparent that many modulators of collagen metabolism inhibit angiogenesis and may offer clinically useful anticancer treatments. Minocycline and other tetracycline derivatives with anticollagenase properties have been shown to be potent inhibitors of angiogenesis. These agents, when administered with other standard cancer therapies, help prolong survival in laboratory animals with solid tumors. Further studies of these biologic response modifiers of tumor progression are under way in the hope that they will offer effective new treatments for cancer in humans.This publication has 59 references indexed in Scilit:
- Identification of an Inhibitor of Neovascularization from CartilageScience, 1990
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Avascular and vascular phases of tumour growth in the chick embryoBritish Journal of Cancer, 1977
- Isolations of a Cartilage Factor That Inhibits Tumor NeovascularizationScience, 1976
- Inhibition of tumor angiogenesis mediated by cartilage.The Journal of Experimental Medicine, 1975
- Tumor Angiogenesis: A Possible Control Point in Tumor GrowthAnnals of Internal Medicine, 1975
- SELF-REGULATION OF GROWTH IN THREE DIMENSIONSThe Journal of Experimental Medicine, 1973
- TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATIONThe Journal of Experimental Medicine, 1972
- Anti-AngiogenesisAnnals of Surgery, 1972
- Transplacental Carcinogenesis by StilbestrolNew England Journal of Medicine, 1971